
Key opinion leaders analyze unmet needs and emerging trends in melanoma treatment based on findings presented at ASCO 2024.
Key opinion leaders analyze unmet needs and emerging trends in melanoma treatment based on findings presented at ASCO 2024.
Dr Lipson continues his discussion as he highlights significant results from the NADINA trial.
Results from the RELATIVITY-047 study on the melanoma landscape are evaluated by Dr Evan Lipson.
Dr Lipson provides insights surrounding combination therapies in melanoma management.
Considerations for neoantigen therapy tailored to specific patient needs is discussed by Dr Lipson.
Key opinion leaders analyze unmet needs and emerging trends in melanoma treatment based on findings presented at ASCO 2024.
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.